EyePoint Pharmaceuticals Inc. (EYPT)’s Financial Results Comparing With CohBar Inc. (NASDAQ:CWBR)

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) and CohBar Inc. (NASDAQ:CWBR), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio EyePoint Pharmaceuticals Inc. 3.06M 70.10 80.31M -1.35 0.00 CohBar Inc. N/A 0.00 14.35M -0.35 0.00 Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of EyePoint Pharmaceuticals Inc. and CohBar Inc. Net Margins Return on Equity Return on Assets EyePoint Pharmaceuticals Inc. -2,624.51% -414.6% -142.9% Volatility & Risk

EyePoint Pharmaceuticals Inc. is 61.00% more volatile than Standard and Poor’s 500 due to its 1.61 beta. CohBar Inc.’s 6.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 1.06 beta.

Liquidity

EyePoint Pharmaceuticals Inc. has a Current Ratio of 2.6 and a Quick Ratio of 2.6. Competitively, CohBar Inc.’s Current Ratio is 33.2 and has 33.2 Quick Ratio. CohBar Inc.’s better ability to pay short and long-term obligations than EyePoint Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both EyePoint Pharmaceuticals Inc. and CohBar Inc. are owned by institutional investors at 56.4% and 9.6% respectively. About 0.6% of EyePoint Pharmaceuticals Inc.’s share are held by insiders. Competitively, CohBar Inc. has 4.5% of it’s share held by insiders.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) EyePoint Pharmaceuticals Inc. -4.66% -4.26% 1.35% 1.81% 77.17% 108.33% CohBar Inc. -12.47% -9.37% -24.31% -61.17% -22.17% -27.97% For the past year EyePoint Pharmaceuticals Inc. has 108.33% stronger performance while CohBar Inc. has -27.97% weaker performance.

Summary

On 6 of the 9 factors CohBar Inc. beats EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company’s pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

Tags:, ,

Add a Comment

Your email address will not be published.